« Pfizer, Teva and Actavis Vie for Ratiopharm Gmbh | Main | Lilly Buys Pfizer's Animal Health Business in EU »

03/08/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b01310f7ba8f8970c

Listed below are links to weblogs that reference Clinical Crashes for Today:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Account Deleted

Thanks most kindly for linking to my post, Bruce.

The latest cediranib data probably signals an end for the drug given it previously failed in lung cancer, unless the glioblastoma data expected later this year is positive.

Oddly, Roche and Biogen still come out of this well, as it means sales of rituximab, it's existing CD20 antibody won't be cannibalised.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada